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Edited by Takashi GojoboriAbstract We have previously identiﬁed an ESE in NF1 exon 37
whose disruption by the pathological mutation c.6792C > G
caused aberrant splicing. We now investigate the RNA-protein
complexes aﬀected by the c.6792C > G mutation observing that
this concurrently decreases the aﬃnity for the positive splicing
factor YB-1 and increases the aﬃnity for the negative splicing
factors, hnRNPA1, hnRNPA2 and a new player in these type
of complexes, DAZAP1. Our ﬁndings highlight the complexity
of the interplay between positive and negative factors in the exon
inclusion/skipping outcome. Furthermore, our observations stress
the role of a wide genomic context in NF1 exon 37 deﬁnition.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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The connection between aberrant splicing and occurrence of
disease is now ﬁrmly recognized as a central issue in the med-
ical research ﬁeld [1,2]. These studies have shown that patho-
logical nucleotide changes can cause aberrant splicing by
disrupting recognition of auxiliary cis-acting splicing regula-
tory elements by speciﬁc trans-acting factors. These regulatory
elements when found in exons are known as exonic splicing
enhancers or silencers (ESE and ESS, respectively). In general,
ESE are recognized by members of the SR-protein family that
promote spliceosome assembly at the splice sites [3]. However,
other positive trans-acting factors have also been identiﬁed, for
example the YB-1 protein [4] and the DEAD-box RNA heli-
case p72 [5] have been shown to bind an A/C-rich sequence
in the alternatively spliced v4 exon of the CD44 gene. The
ESS sequences, on the other hand, have generally been shown
to bind members of the heterogeneous nuclear ribonucleopro-
tein (hnRNP) family, in particular hnRNPA/B [6].
As emphasized by the many splicing systems that are not
easy to model [7] the determinants of splicing regulation are
still poorly understood and it is obvious that a greater knowl-
edge is needed. This would be extremely relevant from the hu-*Corresponding author. Fax: +39 040 3757361.
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doi:10.1016/j.febslet.2008.05.018man genetic disease point of view of clinical diagnosis and for
eventual strategies aimed at reversing aberrant splicing events.
The neuroﬁbromatosis (NF1) gene exhibits a high mutation
rate. In particular, there is a 4-bp region between nucleotides
c.6789 and c.6792 in exon 37 in which the mutations
c.6792C > G and c.6792C > A induce skipping of NF1 exon
37 that preserves an open reading frame [8]. We have previ-
ously studied the eﬀect of both these nucleotide variations on
splicing of NF1 exon 37. Our previous work [9] showed that
the disruption of an ESE delimited by a ACAAC motif, is
the cause of the ineﬃcient inclusion in NF1 mRNA of exon
37 carrying the c.6792C > G and c.6792C > A mutations
found in patients, which in turn was also observed to be neces-
sary for NF1 exon 36 inclusion. Our results also showed that in
the setting of the exon-rich genomic cluster within which NF1
exon 37 is located, early and late transcribed sequences condi-
tion the deﬁnition of speciﬁc exons. Indeed, the inclusion of a
signiﬁcant amount of NF1 genomic sequence in a minigene was
required for correct processing to occur. Speciﬁcally, NF1
exons 34–38 in the case of the wild-type sequence and NF1
exons 31–38 in the case of the sequence carrying the patholog-
ical mutations were found to be necessary in order to obtain
splicing patterns similar to those observed from normal and
diseased patient lymphoblasts, respectively. In this study, we
have now investigated the diﬀerent trans-acting factors that
bind to either the wild-type or mutated ESE and the way their
action is aﬀected by genomic complexity.2. Materials and methods
2.1. Plasmid and minigene constructs
YB1 pGEX-4T and YB-1 pcDNA3-FLAG were gifts from Dr. K.
Kohno. Constructs PTBEx37 wt and c.6792C > G, Ex 31–38 wt and
C6792G have been previously described [9]. DAZAP1 and hnRNPA1
and A2 cDNAs were cloned in the pGEX-3X expression vector, re-
combinant fusion proteins were expressed in Escherichia coli BL21
by overnight induction (0.3 mM IPTG) at room temperature and puri-
ﬁed with glutathione S-Sepharose 4B beads (Amersham Biotech).
ACEsel and ACEmut sequences were inserted in the minigene span-
ning NF1 exons 34–38 through PCR and inserted using the cassette
AfeI/EcoRI.
2.2. Cell culture and transfection and RT-PCR analysis
Sense strands of RNAi oligos (Dharmacon) for hnRNPA1 CAG-
CUGAGGAAGCUCUUCA, for hnRNPA2 GGAACAGUUCC-
GUAAGCUC, for DAZAP1 GAGACUCUGCGCAGCUACU and
YB-1 GGUCAUCGCAACGAAGGUU for helicase p72 CAAGGG-
UACCCCUAUACCUU. siCONTROL non-targeting siRNA #2
against the ﬁreﬂy luciferase gene was used as a control. 3 · 105 HeLa
cells were transfected twice with Oligofectamine (Invitrogen), dis-
tanced 24 h, with 40 lM of corresponding siRNA. 0.5 lg of minigeneblished by Elsevier B.V. All rights reserved.
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ment. Other transfections were performed with Eﬀectene transfection
reagent (Qiagen). Cells were collected 24 h after transfection of the
minigene with RNAwiz (Ambion) and total RNA isolated. RT-PCR
was carried out with primers previously described speciﬁc for these
minigene transcript [9]. The results are representative of at least three
independent experiment. ImageJ software http://rsb.info.nih.gov/ij/
was used to quantify the proportion of the diﬀerent spliced products.
The variability among diﬀerent experiments was <15%.
2.3. RNA probes
RNA probes were obtained by amplifying the NF1 exon 37
sequences from the corresponding minigenes carrying the various
nucleotide transitions. In these cases, the 5 0 oligo carried a T7 polymer-
ase target sequence. Ampliﬁed products were puriﬁed and used for T7
polymerase (Stratagene) driven transcription with or without labeled
[a-32P] UTP. RNA templates prepared in this way and extending from
nt 1–84 and 11–46 of NF1 exon 37 were used for UV-crosslinking,
EMSA, and pull-down assays according to previously described proce-
dures [4,10].
2.4. Antibodies
The puriﬁed GST-DAZAP1 was used for rabbit immunization (New
Zealand strain) according to standard protocols. Anti-hnRNPA1 and
anti-hnRNPA2 antibodies were a gift from Klima Raﬀaella, Anti-YB1
was a gift from Dr. T.A. Cooper. Anti-tubulin was obtained from Sig-
ma. Anti-p72 was obtained from Novus.Fig. 1. Diﬀerential binding of nuclear factors to NF1 exon 37 wild-
type and c.6792C > G RNAs. (A) SDS–PAGE gel (Coomassie stained)
of aﬃnity puriﬁed RNA binding proteins. In the c.6792C > G RNA
two new proteins were identiﬁed, hnRNPA1/2 and DAZAP1. (B)
Diﬀerential binding of these proteins to NF1 exon 37 wild-type and
c.6792C > G RNA in EMSA analysis. Arrow indicates band-shifted
complexes.3. Results and discussion
3.1. Pull-down analysis of the protein proﬁles between wild-type
and c.6792C > G NF1 exon 37
To identify the trans-acting factors whose interaction with the
NF1 exon 37 ESE may have been aﬀected by the c.6792C > G
mutation we performed an aﬃnity puriﬁcation experiment
using wild-type exon 37 and mutated (c.6792C > G) NF1 exon
37 RNA. Interestingly, the binding proﬁles obtained in the
pull-down experiment showed the appearance of two new pro-
teins speciﬁc for the c.6792C > G mutation (Fig. 1A) rather
than the disappearance from wild-type exon 37. These bands
were excised from the gel and identiﬁed through mass spectro-
metric analysis as hnRNPA1/A2, and deleted in azoospermia
associated protein 1 (DAZAP1). hnRNPA1 and A2 normally
bind to sequences that share a core UAG sequence [11] that is
indeed created by the c.6792C > G mutation. DAZAP1 is an
RNA binding protein that according to published data binds
preferentially to poly (U), poly (G) and poly (A) [12].
The creation of new binding aﬃnities of hnRNPA1,
hnRNPA2 and DAZAP1 for the c.6792C > G mutated se-
quence was further tested by EMSA analysis using the recom-
binant proteins. All three proteins show a signiﬁcantly greater
amount of retarded complexes with the labeled c.6792G > C
RNA when compared to the labeled wild-type RNA.
3.2. Functional signiﬁcance of the diﬀerential binding eﬃciency
of hnRNPA1/A2 and DAZAP1 between wild-type and
c.6792C > G NF1 exon 37
To test the functional signiﬁcance of these bindings in medi-
ating NF1 exon 37 splicing inhibition, Hela cells were co-trans-
fected with plasmids expressing each of these proteins along
with NF1 minigenes extending from exons 31–38 carrying the
c.6792C > G mutation or the wild-type sequence. The results
conﬁrm an additional inhibitory eﬀect due to the increased
concentration of hnRNPA1, hnRNPA2 and DAZAP1
(Fig. 2A). This eﬀect is strongest with the over-expression ofhnRNPA1, where correctly processed mRNA is practically ab-
sent, but was also observed to a lesser extent with hnRNPA2
and DAZAP1. Curiously, the ratios of the aberrantly spliced
mRNA (skipping of exon 37 and skipping of exons 37 and
36) were diﬀerent in all three cases of over-expression, suggest-
ing slightly diﬀerent modes of action for each of the three fac-
tors.
In parallel, however, separate siRNA interference experi-
ments against each of hnRNPA1/A2 and DAZAP1 had no sig-
niﬁcant eﬀect on the pre-mRNA processing and only a triple
siRNA against all three proteins resulted in a limited overall
decrease of skipping of NF1 exon 37 with respect to the aber-
rantly spliced products (Fig. 2B).
The fact that the knockdown of these inhibitory trans-acting
factors did not fully recover the correct mRNA processing of
NF1 exons 37 and 36 can be explained by the fact that the
c.6792C > G mutation is not only creating a silencer but also
disrupting an enhancer sequence, as proposed in our previous
work [9], that is evidently necessary for the correct processing
of NF1 exons 37 and 36. If the splicing defect caused by the
c.6792G > C mutation is the result of combined disruption
of the enhancer sequence and the creation of a silencer ele-
ment, it will be important to identify the putative positive fac-
tor(s) that bind to the NF1 exon 37 ESE.
Fig. 2. Inhibitory eﬀect of hnRNPA1, hnRNPA2 and DAZAP1 on NF1 exon 37 splicing. (A) Co-expression of Ex 31-38 c.6792C > G minigene with
hnRNPA1, hnRNPA2 and DAZAP1 expressing plasmids. Lower panel: graph showing the ratio of each mRNA species as percentage. (B) Left
panel, RT-PCR analysis of the eﬀect of triple siRNA depletion of hnRNPA1, hnRNPA2, and DAZAP1 on diﬀerent minigenes. Right panel, Western
blot of the triple siRNA experiment.
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NF1 exon 37
It has been previously suggested through the use of SR
scoring matrices (ESE ﬁnder) that the eﬀects of the
c.6792C > G mutation could be due to the disruption of an
SR protein binding site [1]. The ESE ﬁnder program predicts
the presence of an SRp40 motif between nucleotides c.6789
and c.6795 (score 4.6) that is weakened with the nucleotide
substitution c.6792C > G (score 2.87). We then performed
UV-crosslinking analysis with Hela extract followed by immu-
noprecipitation with monoclonal antibodies against a panel of
the major SR proteins (SF/ASF, SC35, SRp75, SRp55 and
SRp40) with NF1 exon 37 wild-type RNA. As a positive con-
trol, we used the ESE of the Fibronectin EDA exon that had
been previously shown to immunoprecipitate the entire range
of SR proteins being tested [10]. The diﬀerent panels in
Fig. 3A (I–IV) show that none of the more common SR pro-
teins could bind the wild-type NF1 exon 37 sequence at com-
parable levels.
Our previous study [9] highlighted the importance of the
ACAAC motif that resembles the A/C-rich exon splicing en-
hancer sequence found in the CD44 gene that was previously
reported to bind YB-1 [4], suggesting that binding of this fac-
tor may be aﬀected by the c.6792G > C mutation and conse-
quently aﬀecting the mRNA splicing of NF1 exons 36–37.To test the possible YB-1 binding to this ACAAC motif we
performed UV-crosslinking analysis followed by immunopre-
cipitation. As positive controls for this experiment, we used
target sequences previously shown to either cross-link eﬃ-
ciently with YB-1 (ACEsel) or not to bind it (ACEselMut)
[4]. From the total UV-crosslinking proﬁle (Fig. 3B left panel)
a strong band with MW of 50 kDa, consistent with crosslinked
YB-1 was visible in the ACEsel lane and absent in ACEselMut
lane. Corresponding but weaker bands were also present in
both the wild-type and mutated (c.6792G > C) exon 37. To
conﬁrm the identity of these bands as YB-1, these samples
were then immunoprecipitated with an antibody against YB-
1. In the immunoprecipitation (Fig. 3B right panel), we can
see that exon 37 wild-type RNA is able to bind YB-1 albeit
with a much lower aﬃnity than the ACEsel sequences, in part
possibly due to the fact that this contains two copies of the A/
C-rich element that binds BY-1. Nonetheless, this ability de-
creases further in presence of the c.6792C > G mutation.
The diﬀerential binding ability of YB-1 for wild-type and
mutated (c.6792G > C) NF1 exon 37 was conﬁrmed by compe-
tition experiments against the ACEsel binding sequence. In
fact, Fig. 3C shows that the pattern obtained after UV-cross-
linking the ACEsel sequence with Hela extract. The signal
for YB-1 bound by labeled ACEsel sequence is competed oﬀ
by addition of cold ACEsel or wild-type NF1 exon 37 RNAs
Fig. 3. Analysis of positive factors binding to NF1 exon 37. (A) UV-
crosslinking analysis with HeLa nuclear extract of the Fibronectin
EDA exon and the NF1 exon 37 wild-type RNA (I): immunoprecip-
itation with antibody against SF2/ASF (II), SC35 (III), and the
phosphorylated RS domain (IV). SR proteins mobilities are indicated
on the left. (B) Left panel, UV-crosslinking analysis of NF1 Ex 37 wild-
type and c.6792C > G and YB-1 control sequences with HeLa nuclear
extract. Right panel, immunoprecipitation with anti-YB-1. (C) Com-
petition of YB-1 present in HeLa extract and crosslinked to labeled
ACEsel RNA sequence (indicated by arrowhead) with cold ACEsel,
ACEselMut, Ex 37wt and c.6793C > G RNAs (D) UV-crosslinking
competition analysis of puriﬁed recombinant GST-YB-1 bound to
labeled Ex 37wt RNA (arrow on the right) in the presence of increasing
amounts of cold Ex 37wt or c.6792C > G RNAs.
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This diﬀerence between the wild-type and mutated exon 37 for
YB-1 recognition could also be observed in UV-crosslinking
experiments with recombinant GST-YB-1 In this experiment,
puriﬁed YB-1 protein showed eﬃcient UV-crosslinking to a
labeled exon 37 wild-type RNA (Fig. 3D) that could be com-
peted by excess exon 37 wild-type RNA but not by RNA
carrying the c.6792C > G mutation.3.4. Bearing of positive and negative splicing factors in NF1exon
37 splicing
To better delineate the observations which indicate a mech-
anistic role for YB-1 within the functioning of the ESE in NF1
exon 37 and a negative role for hnRNPA1, hnRNPA2 and
DAZAP1 in the presence of the c.6792C > G mutation we
tested if the well established YB-1 binding sequence (ACEsel)
was able to rescue NF1 exon 37 inclusion in the presence of the
c.6792C > G mutation. Through minimal nucleotide changes,
the ACEsel sequence was inserted up-stream of the ESE in
both wild-type and c.6792C > G minigenes extending from
NF1 exons 34–38 (Fig. 4A). These modiﬁcations do not have
any eﬀect on the pre-mRNA splicing pattern of the wild-type
minigene (Fig. 4A, lanes 1 and 2) but are able to rescue the
aberrant splicing pattern previously observed in the minigene
carrying the c.6792G > C mutation (lanes 3 and 4). Hence,
the changes introduced provide the enhancer activity necessary
to overcome both the loss of function of the ESE activity and
the ESS gain of function activity created by the c.6792C > G
mutation.
However, knockdown of YB-1 through siRNA experiments
(Fig. 4B) performed on the ACEsel containing, exon 37
c.6792C > G minigenes did not produce signiﬁcant changes
in the splicing pattern. This suggested a possible redundancy
of YB-1 function. That is, YB-1 might be replaced by other
protein(s) in the interaction with the ACEsel and the A/C-rich
element in NF1 exon 37. A similar phenomena has been ob-
served for some SR proteins [13]. In this respect, it should also
be noted that siRNA experiments against additional potential
candidates that might have replaced YB-1 such as the DEAD-
box RNA helicase p72, were also performed singularly and in
combination with that of YB-1. However, the processing pro-
ﬁle remained unchanged (data not shown).
The results described above did not allow us to draw deﬁni-
tive conclusions on the ACAAC ESE function in NF1 exon 37.
We have then attempted to make the system more sensitive to
variation by studying the processing of NF1 exon 37 isolated
from the genomic context. As outlined in the introduction,
NF1 exon 37 needs early transcribed sequences to be correctly
processed. In fact, a hybrid minigene consisting of NF1 exon
37 together with a limited amount of up- and down-stream
intronic sequence showed approximately only 50% inclusion.
Notwithstanding this, the deleterious eﬀect of the c.6792C >
G mutation was still observed (Fig. 5 lanes 1 and 3). This
minigene provided an ideal substrate with which to study the
functioning of both the wild-type and mutated ESE without
the masking of other NF1 genomic elements that deﬁne exon
37.
In this minigene, where the wild-type NF1 exon 37 process-
ing is partially deﬁcient, the knockdown of YB-1 has a clear
deleterious eﬀect (Fig. 5, lanes 1 and 2). Furthermore, we also
observed that the depletion of hnRNPA1, hnRNPA2 and DA-
ZAP1 was unable to rescue to any extent the correctly pro-
cessed RNA in the PTBEx37 minigene carrying the
c.6792G > C mutation (Fig. 5, lanes 3 and 4). An explanation
of this result is that in this impoverished minigene context the
elimination of the negative trans-acting factors cannot induce
NF1 exon 37 to become included in the mRNA, as its recogni-
tion is deﬁned by both the genomic context and the ESE, and
when both of these are lacking exon recognition is impossible.
We then introduced in the PTBEx37 c.6793C > G minigene the
nucleotide changes that generate the ACEsel sequence up-
Fig. 4. The ACEsel sequence rescues c.6792C > G aberrant splicing. (A) Upper panel, schematic representation of the minigenes extending from NF1
exons 34–38. Lower panel, RT-PCR analysis of these minigenes. (B) RT-PCR analysis of eﬀects of depleting YB-1 (Western blot, left panels) on
processing of minigenes carrying the Ex.37wt and the c.6792C > G mutation together with the ACEsel sequence insertion (right panel).
Fig. 5. Bearing of trans-acting factors in the deﬁnition of NF1 exon 37. Upper panel, schematic representation of the PTB minigene carrying the
single exon 37 sequence. Lower panel eﬀects of depleting diﬀerent combinations of YB-1, hnRNPA1, hnRNPA2 and DAZAP1 in the presence of the
PTBEx37, PTBEx37 c.6792C > G, and ACEsel-PTBEx37 C6792G minigenes.
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creased the correctly processed RNA (Fig. 5, lanes 3 and 5).
However, they did so to a lower extent than that observed in
the minigene carrying the larger heterologous context (Fig.
4A, lane 4), possibly indicating that in this reduced context
the binding of negative trans-acting factors (hnRNPA1, A2
and DAZAP1) are more inﬂuential. This is a similar eﬀect tothat observed for YB-1. To test if this was the case we then
transfected the PTB NF1 exon 37 carrying both the ACEsel
nucleotide transition and the c.6792C > G mutation (ACE-
sel-PTBEx37 c.6792C > G) along with siRNAs for hnRNPA1,
hnRNPA2 and DAZAP1 individually and in combination.
After RT-PCR (Fig. 5, lanes 6–9) we observed that, with the
ACEsel enhancer sequence present, depletion of hnRNPA1
2236 N. Skoko et al. / FEBS Letters 582 (2008) 2231–2236greatly increased the amount NF1 exon 37 inclusion albeit still
not to the levels observed in the wild-type minigene (lanes 5
and 1). Knockdown of hnRNPA2 or DAZAP individually
did not have any signiﬁcant eﬀect on NF1 exon 37 inclusion
(lanes 7 and 8). However, if depletion of these two factors
was performed in combination with hnRNPA1 a synergic ef-
fect could be observed, as the inclusion of exon 37 increased
well beyond the PTBEx37 wild-type levels (lanes 1 and 9).4. Conclusion
Our results indicate that c.6792C > G induces aberrant splic-
ing of NF1 exons 36–37 through an extremely complex set of
events. Firstly, there is the reduction of the NF1 exon 37
ESE aﬃnity for positive trans-acting factor(s), of which YB-
1 is an example. Secondly, the concomitant increase of the mu-
tated ESE aﬃnity for DAZAP1 and hnRNPA1 and
hnRNPA2, eﬀectively turning it into an ESS and leading to
a higher degree of exon 37 exclusion. than would have other-
wise occurred with just the disruption of the ESE, possibly also
antagonizing any residual positive eﬀect of the YB-1 or YB-1
like protein. Of particular interest is the fact that the depletion
of all three negative factors results in the maximum reduction
of the negative regulation of splicing. Our data extend the evi-
dence that aside disruption of ESEs the concomitant creation
of ESS elements may be a common event in human pathology.
This is something that has to be taken into consideration when
developing therapeutic strategies aimed at correcting splicing
defects. Of all the proteins identiﬁed in this study, the role that
DAZAP1 plays in the regulating exon 37 splicing process is a
new one as is has not been previously suggested to be a splicing
factor [12]. In keeping with this role, we have observed a sim-
ilar function in another system [14]. This factor has a high level
of similarity with many hnRNP proteins in the RNP motifs
[15] and shares a high degree of homology with Drosophila
hnRNP27C, an hnRNPA/B-like protein that plays a func-
tional role in P-element third intron splicing inhibition [12].
Interestingly, band shift experiments carried out in the present
study demonstrate similar binding properties of DAZAP1 to
the already well known negative splicing factors hnRNPA1
and A2, suggesting that this protein may be present in other
systems working in synergy or instead of hnRNPA1 and A2.
In this respect, as recently highlighted, hnRNPA1 role as neg-
ative splicing factor is sequence speciﬁc with depletion of the
protein not always suﬃcient to rescue normal splicing indica-
tive that hnRNPA1-binding is not suﬃcient to deﬁne a func-
tional ESS [16].
Our data also highlight the importance of the context in
which an ESE/ESS ﬁnds itself. In fact, we have observed that
in the presence of a wider genomic context both the silencing
eﬀect of the ESS and the enhancer eﬀect of the ESE were less
determinant for the inclusion the NF1 exon 37 than when this
exon was introduced in a heterologous system. This observa-tion indicates the importance of carefully evaluating the geno-
mic context in diagnostic and clinical analyses whenever
possible.
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